Corline Biomedical AB (CLBIO) — Cash Flow-to-Debt Ratio
Corline Biomedical AB (CLBIO) has a Cash Flow-to-Debt Ratio of -1.40x as of December 2025, meaning its operating cash flow of Skr-6.76 Million could theoretically repay -1% of its total liabilities (Skr4.82 Million) in one year. Check Corline Biomedical AB cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Corline Biomedical AB Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Corline Biomedical AB across 13 annual periods. Also explore CLBIO current and non-current assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Corline Biomedical AB (2013–2025)
Year-by-year debt coverage analysis for Corline Biomedical AB. For market capitalisation and broader financial context, see Corline Biomedical AB (CLBIO) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.67x | Skr-17.69 Million | Skr4.82 Million | ▼ -233.5% |
| 2024 | -1.10x | Skr-8.64 Million | Skr7.85 Million | ▼ -943.5% |
| 2023 | 0.13x | Skr886.00K | Skr6.79 Million | ▲ +114.6% |
| 2022 | -0.90x | Skr-6.45 Million | Skr7.19 Million | ▼ -74.9% |
| 2021 | -0.51x | Skr-4.83 Million | Skr9.43 Million | ▲ +36.7% |
| 2020 | -0.81x | Skr-5.07 Million | Skr6.25 Million | ▲ +74.0% |
| 2019 | -3.12x | Skr-13.84 Million | Skr4.43 Million | ▼ -505.0% |
| 2018 | -0.52x | Skr-4.10 Million | Skr7.95 Million | ▲ +43.0% |
| 2017 | -0.90x | Skr-4.98 Million | Skr5.50 Million | ▲ +68.3% |
| 2016 | -2.85x | Skr-7.21 Million | Skr2.53 Million | ▼ -152.3% |
| 2015 | -1.13x | Skr-4.23 Million | Skr3.74 Million | ▼ -450.0% |
| 2014 | -0.21x | Skr-2.32 Million | Skr11.29 Million | ▲ +57.1% |
| 2013 | -0.48x | Skr-2.76 Million | Skr5.76 Million | — |